These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 17671156)

  • 21. [Second-line treatment of non-small-cell lung cancers].
    Moro-Sibilot D
    Rev Pneumol Clin; 2006 Dec; 62(6 Pt 2):2S37-40. PubMed ID: 17404538
    [No Abstract]   [Full Text] [Related]  

  • 22. c-Met inhibition.
    Salgia R
    Clin Adv Hematol Oncol; 2006 Nov; 4(11):823-4. PubMed ID: 17143251
    [No Abstract]   [Full Text] [Related]  

  • 23. ALK inhibitors in non-small cell lung cancer: how many are needed and how should they be sequenced?
    Shaw AT
    Clin Adv Hematol Oncol; 2017 Dec; 15(12):941-945. PubMed ID: 29315286
    [No Abstract]   [Full Text] [Related]  

  • 24. [German Society of Pneumology and Respiratory Medicine--thoracic oncology in Germany--Update 2007]].
    Bock S
    Pneumologie; 2007 Jun; 61(6):347-8. PubMed ID: 17566950
    [No Abstract]   [Full Text] [Related]  

  • 25. Combination therapies with mitogen-activated protein kinase kinase inhibitors and immune checkpoint inhibitors in non-small cell lung cancer.
    Xu JL; Wang XZ; Jiang HN; Chen Y; Wang R; Shu YQ
    Chin Med J (Engl); 2020 Oct; 133(20):2495-2497. PubMed ID: 32941237
    [No Abstract]   [Full Text] [Related]  

  • 26. Mobocertinib (Exkivity) for non-small cell lung cancer.
    Med Lett Drugs Ther; 2022 Nov; 64(1664):e197-e198. PubMed ID: 36397196
    [No Abstract]   [Full Text] [Related]  

  • 27. Practice-Changing Findings.
    Fidler MJ
    Oncology (Williston Park); 2015 Jul; 29(7):502-4. PubMed ID: 26178345
    [No Abstract]   [Full Text] [Related]  

  • 28. Improving brain penetration of kinase inhibitors in lung cancer patients with oncogene dependency.
    Remon J; Soria JC
    Ann Oncol; 2017 Feb; 28(2):196-198. PubMed ID: 28426099
    [No Abstract]   [Full Text] [Related]  

  • 29. Measurement of phosphoinositide 3-kinase activity.
    Ward SG
    Methods Mol Biol; 2000; 138():163-72. PubMed ID: 10840756
    [No Abstract]   [Full Text] [Related]  

  • 30. Sequencing of MET Inhibitors in Lung Cancer: Have We Met the Target?
    Kim CG; Cho BC; Lim SM
    J Thorac Oncol; 2021 May; 16(5):709-711. PubMed ID: 33896567
    [No Abstract]   [Full Text] [Related]  

  • 31. Small-Molecule RAS Inhibitors as Anticancer Agents: Discovery, Development, and Mechanistic Studies.
    Shetu SA; Bandyopadhyay D
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409064
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypoxic Microenvironment-Induced Reduction in PTEN-L Secretion Promotes Non-Small Cell Lung Cancer Metastasis through PI3K/AKT Pathway.
    Song X; He J; Shi B; Han Y
    Evid Based Complement Alternat Med; 2022; 2022():6683104. PubMed ID: 35280516
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A multiscale biophysical model for the recruitment of actin nucleating proteins at the membrane interface.
    Fatunmbi O; Bradley RP; Kandy SK; Bucki R; Janmey PA; Radhakrishnan R
    Soft Matter; 2020 Jun; 16(21):4941-4954. PubMed ID: 32436537
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of Indole Scaffolds as Pharmacophores in the Development of Anti-Lung Cancer Agents.
    Dhuguru J; Skouta R
    Molecules; 2020 Apr; 25(7):. PubMed ID: 32244744
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modulation of proliferation factors in lung adenocarcinoma with an analysis of the transcriptional consequences of genomic EGFR activation.
    Kucherlapati MH
    Oncotarget; 2019 Dec; 10(65):6913-6933. PubMed ID: 31857847
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CXCR7 Reactivates ERK Signaling to Promote Resistance to EGFR Kinase Inhibitors in NSCLC.
    Becker JH; Gao Y; Soucheray M; Pulido I; Kikuchi E; Rodríguez ML; Gandhi R; Lafuente-Sanchis A; Aupí M; Alcácer Fernández-Coronado J; Martín-Martorell P; Cremades A; Galbis-Caravajal JM; Alcácer J; Christensen CL; Simms P; Hess A; Asahina H; Kahle MP; Al-Shahrour F; Borgia JA; Lahoz A; Insa A; Juan O; Jänne PA; Wong KK; Carretero J; Shimamura T
    Cancer Res; 2019 Sep; 79(17):4439-4452. PubMed ID: 31273063
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and Tolerability of Phosphatidylinositol-3-Kinase (PI3K) Inhibitors in Oncology.
    Curigliano G; Shah RR
    Drug Saf; 2019 Feb; 42(2):247-262. PubMed ID: 30649751
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PI3K/AKT inhibition induces compensatory activation of the MET/STAT3 pathway in non-small cell lung cancer.
    Bian C; Liu Z; Li D; Zhen L
    Oncol Lett; 2018 Jun; 15(6):9655-9662. PubMed ID: 29928341
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lung Endothelial MicroRNA-1 Regulates Tumor Growth and Angiogenesis.
    Korde A; Jin L; Zhang JG; Ramaswamy A; Hu B; Kolahian S; Guardela BJ; Herazo-Maya J; Siegfried JM; Stabile L; Pisani MA; Herbst RS; Kaminski N; Elias JA; Puchalski JT; Takyar SS
    Am J Respir Crit Care Med; 2017 Dec; 196(11):1443-1455. PubMed ID: 28853613
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of miRNA let-7 and its major targets in prostate cancer.
    Wagner S; Ngezahayo A; Murua Escobar H; Nolte I
    Biomed Res Int; 2014; 2014():376326. PubMed ID: 25276782
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.